論文・技術情報追加のお知らせ

1. Vonoprazan-associated Clostridioides difficile infection: an analysis of the Japanese Adverse Drug Event Report and the FDA Adverse Event Reporting System.

ボノプラザンはPPIよりもCDIとの関連が強い

対象DB：FAERS,JADER

2. A systematic review and Bayesian analysis of the adverse effects of dienogest.

ディエノゲストの副作用は一般的に軽度で、安全性が高いが、重篤な副作用も報告されている

対象DB：FAERS

3. Drug-associated porphyria: a pharmacovigilance study.

ポルフィリア関連の有害事象を引き起こす薬剤52種類を特定

対象DB：FAERS

4. Clostridioides difficile Infection Risk Following Different Antibiotics: Insights from Multi-source Medical Data.

抗生物質のCDIリスクは薬剤ごとに異なり、リンスコマイシンが最も高い

対象DB：FAERS

5. Analysis of eplerenone in the FDA adverse event reporting system (FAERS) database: a focus on overall patient population and gender-specific subgroups.

エプレレノンの副作用には高カリウム血症や肝障害が含まれる

対象DB：FAERS

6. Safety assessment of Yasmin: Real-world adverse event analysis using the FAERS database.

ヤスミンの副作用には肝胆道障害や精神障害が含まれる

対象DB：FAERS

7. Post-marketing safety concern of PI3K inhibitors in the cancer therapies: an 8-year disproportionality analysis from the FDA adverse event reporting system.

PI3K阻害剤は代謝障害や消化器系障害を引き起こす

対象DB：FAERS

8. A disproportionality analysis of CDK4/6 inhibitors in the FDA adverse event reporting system (FAERS).

CDK4/6阻害剤は肺毒性、骨髄抑制、皮膚反応を引き起こす可能性

対象DB：FAERS

9. A safety signal for congenital strabismus associated with valproic acid: A pharmacovigilance analysis utilizing the FDA Adverse Event Reporting System database.

バルプロ酸が先天性斜視と強く関連することが確認

対象DB：FAERS

10. A real-world disproportionality analysis of cyclosporine from the FDA Adverse Event Reporting System (FAERS) database.

シクロスポリンの新たな副作用がFAERSで確認され、安全性情報を提供

対象DB：FAERS

11. Signal of dementia with proton pump inhibitor after minimizing competition bias: an updated disproportionality analysis.

PPIと認知症の関連性が確認され、さらなる研究が必要

対象DB：FAERS

12. Fluoroquinolones-related psychiatric adverse events: a real-world retrospective and pharmacovigilance database analysis.

フルオロキノロンによる精神的副作用は、特に若年層と女性で多く、迅速な対処が重要

対象DB：FAERS

13. Risk of drug-induced angioedema: a pharmacovigilance study of FDA adverse event reporting system database.

FAERS分析で、リシノプリルなどの薬剤の浮腫リスクが高いことが判明

対象DB：FAERS

14. Post-marketing safety surveillance of fostamatinib: an observational, pharmacovigilance study leveraging FAERS database.

フォスタマチニブの有害事象をFAERSデータで分析

対象DB：FAERS

15. Central serous chorioretinopathy secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS).

CSCRと薬剤の関連をFAERSで初めて評価。グルココルチコイドなどが関連

対象DB：FAERS

16. Disproportionality analysis of data from VigiBase and other global product safety databases on toxicity of iron chelating agents.

鉄キレート剤の副作用に関する新たなシグナルを発見

対象DB：FAERS,VigiBase

17. Characterizing immune checkpoint inhibitor-related cutaneous adverse reactions: A comprehensive analysis of FDA adverse event reporting system (FAERS) database.

免疫チェックポイント阻害剤の皮膚有害事象は重篤な場合もあり、早期発見と管理が重要

対象DB：FAERS

18. Comparing the adverse effects of ketamine and esketamine between genders using FAERS data.

エスケタミンとケタミンの有害事象は性別で異なり、個別対応が必要

対象DB：FAERS

19. A Pharmacovigilance Study on Clozapine in the Food and Drug Administration Adverse Event Reporting System: A Regional Comparative Analysis.

クロザピン関連有害事象に地域差があり、アジアでは発熱や唾液分泌過多が多く報告

対象DB：FAERS

20. A Real-World Analysis of Post-Marketing Surveillance Data Assessing the Incidence of Hyperkalemia or Acute Kidney Injury in Patients on Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin-Receptor Blockers.

RASI使用でのAKIや高カリウム血症リスクが高く、ACEIとARB併用でさらにリスク増大

対象DB：FAERS

21. Drug-Associated Acute Kidney Disease: Data From a World Pharmacovigilance Database.

薬剤による急性腎疾患（AKD）は多く、VigiBaseで高い報告率を示す

対象DB：VigiBase

22. Integrase inhibitor drugs during pregnancy and congenital anomalies: A case/non-case study from the global pharmacovigilance database VigiBase(R).

INI薬剤（特にラルテグラビル、エルビテグラビル、ドルテグラビル）は特定の先天異常リスクが示唆された

対象DB：VigiBase

23. Time from admission to the onset of methicillin-resistant Staphylococcus aureus bacteremia in a single acute care hospital in Japan.

日本のMRSA菌血症は入院期間長く、若年層や高齢者に影響大

対象DB：DPC

24. Prognostic Factors of In-hospital Mortality in Patients without Human Immunodeficiency Virus Infection with Pneumocystis Pneumonia: A Retrospective Cohort Study.

非HIV PCP患者の入院死亡率は年齢、性別、合併症などが影響

対象DB：DPC

25. Outcomes after hip fracture surgery in patients receiving non-steroidal anti-inflammatory drugs alone, acetaminophen alone, or both.

アセトアミノフェンとNSAIDsの併用は、入院中の合併症を減少させる

対象DB：DPC

26. Early surgical treatment using regional clinical pathways to reduce the length of postoperative hospital stay in hip fracture patients: A retrospective analysis using the Japanese Diagnosis Procedure Combination database.

早期手術と地域別治療計画が股関節骨折の入院期間短縮に有効

対象DB：DPC

27. Temporal trends and regional variations in operative vaginal deliveries in Japan: A national representative cohort study.

日本の分娩方法における地域差と動向分析

対象DB：NDB

28. Associations of the staffing structure of intensive care units and high care units on in-hospital mortality among patients with sepsis: a cross-sectional study of Japanese nationwide claims data.

ICUの組織構造が重症敗血症患者の院内死亡率に影響

対象DB：NDB

29. Trends in Psychiatric Day Care Practices in Japan: An Analysis Using the National Database of Health Insurance Claims Open Data.

日本の精神科デイケア利用が減少、特に緊急事態宣言時に顕著

対象DB：NDB

30. Neurectomy for allergic rhinitis in Japan: Increasing trends and surgeon preferences.

日本ではアレルギー性鼻炎手術が増加、特に簡便な神経切除が選好される

対象DB：NDB

31. Outcomes of Early Versus Delayed Anemia Treatment in Nondialysis-Dependent CKD.

貧血治療の遅延は心血管イベントと全死亡リスクを増加

対象DB：MDV

32. A New Validated Approach for Identifying Childhood Immunizations in Electronic Health Records in the United Kingdom.

新しいアルゴリズムで予防接種のカバレッジを正確に推定

対象DB：CPRD

33. Estimating disease burden using national linked electronic health records: a study using an English population-based cohort.

国民の電子健康記録で疾患の負担を詳細に推定

対象DB：CPRD

34. Association of Dose of Inhaled Corticosteroids and Frequency of Adverse Events.

高用量吸入コルチコステロイドは心血管疾患や肺炎のリスクを増加

対象DB：CPRD

35. Underlying disease risk among fatigued patients: a population-based cohort study in primary care.

疲労を訴える高齢男性は癌のリスクが高い

対象DB：CPRD

36. Predictive value of abnormal blood tests for detecting cancer in primary care patients with nonspecific abdominal symptoms: A population-based cohort study of 477,870 patients in England.

腹部症状のがんリスク評価に血液検査が有用

対象DB：CPRD

37. Use of cholesterol-lowering medications in relation to risk of primary liver cancer in the Clinical Practice Research Datalink.

コレステロール吸収阻害薬は肝癌リスクを低減

対象DB：CPRD

38. The economic burden of cancer, coronary heart disease, dementia, and stroke in England in 2018, with projection to 2050: an evaluation of two cohort studies.

2018年の主要4疾患の経済負担を推定し、2050年まで予測

対象DB：CPRD

39. Changes in the incidence and prevalence of systemic lupus erythematosus between 1990 and 2020: an observational study using the Clinical Practice Research Datalink (CPRD).

SLEの有病率は30年間で5倍増加

対象DB：CPRD

40. Effectiveness of pneumococcal vaccination in adults with common immune-mediated inflammatory diseases in the UK: a case-control study.

肺炎球菌ワクチンは免疫関連炎症疾患患者の肺炎を予防

対象DB：CPRD

41. Comparison of renal prognosis between dipeptidyl peptidase-4 inhibitor users and non-users.

DPP-4阻害薬使用者は非使用者より腎予後が良好

対象DB：DeSC

42. BP classification using the 2017 ACC/AHA guideline with risk of cardiovascular events in older individuals.

ステージ1高血圧は高齢者の心血管疾患リスクを増加

対象DB：DeSC